Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

Share this content:
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

Sponsors and Collaborators
Mayo Clinic
Alexion Pharmaceuticals

Contact
Cindy M. Groettum
507-266-8725
cgroettum@mayo.edu

Principal Investigator
Mark Stegall, MD, Mayo Clinic

ClinicalTrials.gov Identifier
NCT01106027

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters